Producing recombinant human BIRC5 in E. coli involves several steps. First, cloning the gene of interest into a vector with an N-terminal 6xHis-SUMO-tag gene. The gene of interest codes for the 1-142aa of human BIRC5. And then, transforming the recombinant vector into E. coli cells. Growing the E. coli cells to induce protein expression. The cells are lysed to release the BIRC5 protein, which is purified using affinity chromatography. Finally, the purity of the harvested recombinant BIRC5 protein is checked with SDS-PAGE, exceeding 90%.
Human BIRC5, also known as survivin, is a 16.5 kDa monomer protein with 142 amino acid residues. It is encoded by the BIRC5 gene located on human chromosome 17q25.3 [1]. BIRC5 has been found to play a crucial role in the development and advancement of various cancers, including prostate cancer, endometrial cancer, and lung adenocarcinoma [2][3][4]. It is a member of the inhibitor of apoptosis proteins (IAPs) family, which includes proteins such as XIAP, cIAP1, cIAP2, Livin, and Apollon [5][6]. BIRC5 contains a baculoviral IAP repeat (BIR) domain that binds to caspases and a C-terminal ubiquitin ligase domain responsible for posttranslationally attaching ubiquitin to target proteins [7]. In cancer, BIRC5 has been associated with chemoresistance, metastasis, and tumor progression [8][9]. Studies have shown that BIRC5 is up-regulated in various cancers, influencing factors like radiosensitivity in lung adenocarcinoma [4]. Additionally, BIRC5 has been identified as one of endometrial cancer's most differentially expressed genes [3].
References:
[1] S. Yesupatham, C. Dayanand, S. Mohiyuddin, & M. Kumar, An insight into survivin in relevance to hematological, biochemical and genetic characteristics in tobacco chewers with oral squamous cell carcinoma, Cells, vol. 12, no. 10, p. 1444, 2023. https://doi.org/10.3390/cells12101444
[2] L. Wang, Y. Yao, C. Xu, X. Wang, D. Wu, & H. Zhe, Exploration of the tumor mutational burden as a prognostic biomarker and related hub gene identification in prostate cancer, Technology in Cancer Research & Treatment, vol. 20, p. 153303382110521, 2021. https://doi.org/10.1177/15330338211052154
[3] S. Mamoor, Over-expression of baculoviral iap repeat containing 5 in human endometrial cancer.,, 2021. https://doi.org/10.31219/osf.io/h85cd
[4] S. Chen, F. Han, D. Huang, J. Meng, J. Chu, M. Wanget al., Fe3o4 magnetic nanoparticle-enhanced radiotherapy for lung adenocarcinoma via delivery of sibirc5 and as-odn, Journal of Translational Medicine, vol. 19, no. 1, 2021. https://doi.org/10.1186/s12967-021-02971-7
[5] M. Saleem, M. Qadir, N. Perveen, B. Ahmad, U. Saleem, & T. Irshad, Inhibitors of apoptotic proteins: new targets for anticancer therapy, Chemical Biology & Drug Design, vol. 82, no. 3, p. 243-251, 2013. https://doi.org/10.1111/cbdd.12176
[6] K. Sun, L. Qi, Z. Chen, T. Chen, & J. Zhang, Expression of livin and plgf in human osteosarcoma is associated with tumor progression and clinical outcome, Oncology Letters, 2018. https://doi.org/10.3892/ol.2018.9239
[7] L. Dietz, C. Ellison, C. Riechmann, C. Cassidy, F. Felfoldi, A. Pinto-Fernándezet al., Structural basis for smac-mediated antagonism of caspase inhibition by the giant ubiquitin ligase birc6, Science, vol. 379, no. 6637, p. 1112-1117, 2023. https://doi.org/10.1126/science.ade8840
[8] P. Branco, P. Jimenez, J. Machado-Neto, & L. Costa-Lotufo, Birc5 (baculoviral iap repeat containing 5), Atlas of Genetics and Cytogenetics in Oncology and Haematology, no. 7, 2019. https://doi.org/10.4267/2042/70468
[9] G. Jia, Y. Wang, Y. Yu, & X. Wang, Long non‑coding rna nr2f1‑as1 facilitates the osteosarcoma cell malignant phenotype via the mir‑485‑5p/mir‑218‑5p/birc5 axis, Oncology Reports, 2020. https://doi.org/10.3892/or.2020.7698
